SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Philippe Menu Sells 7,394 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 7,394 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $60,113.22. Following the sale, the insider owned 200,993 shares in the company, valued at $1,634,073.09. The trade was a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $28,500.00.

SOPHiA GENETICS Stock Up 2.1%

Shares of NASDAQ SOPH opened at $7.30 on Friday. The stock has a market capitalization of $612.40 million, a P/E ratio of -6.35 and a beta of 0.95. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98. The firm’s 50 day simple moving average is $7.88 and its two-hundred day simple moving average is $6.15. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in the company. Maven Securities LTD purchased a new position in shares of SOPHiA GENETICS in the second quarter valued at about $866,000. AXQ Capital LP purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth about $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth about $9,809,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS in the second quarter worth about $567,000. Finally, Royal Bank of Canada grew its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on SOPH shares. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $10.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.